Dynavox Group (DYVOX) investor relations material

Executive summary

• Revenue grew 16% year-over-year in local currencies for Q2 2026, reaching SEK 670 million, with robust global demand and broad-based growth across geographies and product groups.

• Operating profit surged 137% to SEK 105 million, with an operating margin of 15.7%, reflecting improved profitability and operational efficiency.

• Completed acquisition of Italian reseller SR Labs Healthcare, expanding direct market presence in Europe and supporting future scalability.

• Successfully rolled out a new ERP system across all main legal entities, enhancing scalability.

• Filed a lawsuit in the U.S. against AbleNet to protect intellectual property and address market confusion.

Financial highlights

• Q2 revenue reached SEK 670 million, with 16% currency-adjusted growth and 13% organic growth; gross margin improved to 70%, up 2.6 percentage points year-over-year.

• EBIT was SEK 105 million (up from SEK 44 million last year), with an EBIT margin of 15.7% (up from 7.4%).

• Basic EPS increased to SEK 0.70 per share, up 150–155% year-over-year.

• Cash flow after investments was SEK 67 million, up 167% from last year.

• Dividend of SEK 53 million paid; cash at hand SEK 223 million, net debt SEK 882 million, net debt/EBITDA at 1.6x.

Outlook and guidance

• Long-term target to grow revenue by 20% per year (currency-adjusted, including M&A); EBIT margin goal to reach and exceed 15% annually.

• No material impact from macroeconomic or policy changes; normal seasonality expected for the second half.

• Dividend policy to distribute at least 40% of available net profits via dividends or share repurchases.

• Focus remains on operational efficiency, scaling, and improving go-to-market execution.